Intervention not reported
Adverse events ‐ hepatopathy · people with cardiovascular disease or at high risk of cardiovascular disease
The intervention showed no clear difference in adverse events ‐ hepatopathy (low certainty).
1 finding from 1 review
- Ezetimibe for the prevention of cardiovascular disease and all‐cause mortality events 2018 · Cochrane Headline outcomes onlyRR 1.14 [0.96, 1.35]4 studies · 20687 participantsLow